Patents Assigned to One Lambda
-
Patent number: 11608530Abstract: A method providing next generation sequencing (NGS)-based high-resolution HLA typing as a routine clinical test. The method uses a multiplex PCR primer design for amplifying multiple human leukocyte antigen (HLA) Class I and Class II genes in a single reaction for NGS. The test quality is improved and the protocol for typing multiple HLA genes is simplified because the number of amplification reactions are reduced nearly 10-fold, to yield a substantially equimolar ratio of individual HLA gene amplification products. The invention eliminates an amplicon pooling step, reducing the reagent cost, and required sample DNA quantity.Type: GrantFiled: April 17, 2019Date of Patent: March 21, 2023Assignee: ONE LAMBDA, INC.Inventors: Jar-How Lee, Katsuyuki Saito
-
Patent number: 11460470Abstract: The invention is directed to engineered Fc gamma receptor type III (Fc?II, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).Type: GrantFiled: February 5, 2020Date of Patent: October 4, 2022Assignee: One Lambda, Inc.Inventors: Jar-How Lee, Neng Jen Remi Shih, Julie Nguyen, Rui Pei
-
Patent number: 10571468Abstract: The invention is directed to engineered Fc gamma receptor type III (Fc?111, HNA-1) polypeptides and use of these polypeptides to detect antibodies specific for human neutrophil antigens (HNA). The invention is also directed to methods for the diagnosing and determining susceptibility for developing Transfusion Reaction Acute Lung (TRALI).Type: GrantFiled: May 7, 2015Date of Patent: February 25, 2020Assignee: ONE LAMBDA, INC.Inventors: Jar-How Lee, Neng Jen Remi Shih, Julie Nguyen, Rui Pei
-
Patent number: 9988671Abstract: The invention provides methods for detecting target nucleic acid sequences with diagnostic probes including first and second probe regions that are substantially complementary to first and second target regions respectively on a target nucleic acid strand wherein the first probe region is located 5? to the second probe region. The first probe region is substantially complementary to the first target region, on the target nucleic acid strand, which also includes a second target region, wherein when the first target region is contiguous with the second target region on the target nucleic acid strand, then the first and second probe regions on the diagnostic probe are separated by a spacer region of nucleic acid.Type: GrantFiled: August 14, 2013Date of Patent: June 5, 2018Assignee: ONE LAMBDA, INC.Inventors: Katsuyuki Saito, Jar-How Lee, Lindley Blair
-
Patent number: 9354238Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.Type: GrantFiled: December 23, 2014Date of Patent: May 31, 2016Assignee: ONE LAMBDA, INC.Inventors: Paul Terasaki, Adam Idica, Chun-Tsan Deng
-
Patent number: 9250247Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: GrantFiled: December 11, 2013Date of Patent: February 2, 2016Assignee: ONE LAMBDAInventors: Jar-How Lee, Rui Pei, Thao Nong
-
Patent number: 8927290Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.Type: GrantFiled: February 16, 2011Date of Patent: January 6, 2015Assignee: One Lambda, Inc.Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
-
Publication number: 20140272976Abstract: The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.Type: ApplicationFiled: June 2, 2014Publication date: September 18, 2014Applicant: ONE LAMBDAInventors: Jar-How Lee, Terrence Chen, Thoa Nong
-
Patent number: 8748090Abstract: The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.Type: GrantFiled: May 2, 2008Date of Patent: June 10, 2014Assignee: One Lambda, Inc.Inventors: Jar-How Lee, Terrence Chen, Thoa Nong
-
Publication number: 20140099733Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: ApplicationFiled: December 11, 2013Publication date: April 10, 2014Applicant: One LambdaInventors: Jar-How Lee, Rui Pei, Thao Nong
-
Patent number: 8628932Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: GrantFiled: March 9, 2011Date of Patent: January 14, 2014Assignee: One LambdaInventors: Jar-How Lee, Rui Pei, Thoa Nong
-
Publication number: 20130330725Abstract: The invention provides methods for detecting target nucleic acid sequences with diagnostic probes including first and second probe regions that are substantially complementary to first and second target regions respectively on a target nucleic acid strand wherein the first probe region is located 5? to the second probe region. The first probe region is substantially complementary to the first target region, on the target nucleic acid strand, which also includes a second target region, wherein when said first target region is contiguous with the second target region on the target nucleic acid strand, then the first and second probe regions on the diagnostic probe are separated by a spacer region of nucleic acid.Type: ApplicationFiled: August 14, 2013Publication date: December 12, 2013Applicant: ONE LAMBDAInventors: Katsuyuki Saito, Jar-How Lee, Lindley Blair
-
Patent number: 8512953Abstract: The invention provides methods for detecting target nucleic acid sequences with diagnostic probes including first and second probe regions that are substantially complementary to first and second target regions respectively on a target nucleic acid strand wherein the first probe region is located 5? to the second probe region. The first probe region is substantially complementary to the first target region, on the target nucleic acid strand, which also includes a second target region, wherein when said first target region is contiguous with the second target region on the target nucleic acid strand, then the first and second probe regions on the diagnostic probe are separated by a spacer region of nucleic acid.Type: GrantFiled: September 24, 2002Date of Patent: August 20, 2013Assignee: One LambdaInventors: Katsuyuki Saito, Jar-How Lee, Lindley Blair
-
Publication number: 20110250619Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for methods of removing antibodies specific for denatured HLA antigens or antibodies specific for native HLA antigens from a serum sample. In addition, the invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: ApplicationFiled: March 9, 2011Publication date: October 13, 2011Applicant: ONE LAMBDAInventors: Jar-How Lee, Rui Pei, Thoa Nong
-
Publication number: 20110201026Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.Type: ApplicationFiled: February 16, 2011Publication date: August 18, 2011Applicant: One Lambda, Inc.Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
-
Patent number: 7972804Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: GrantFiled: June 27, 2008Date of Patent: July 5, 2011Assignee: One LambdaInventors: Jar-How Lee, Rui Pei, Thoa Nong
-
Publication number: 20090142762Abstract: The present invention relates to methods for screening for binding interactions using multiple sets of microparticles, wherein said set has the same identifiable characteristic and wherein one of more sets comprise subsets of microparticles and said subset presents at least one unique probe that acts as a binding partner for a target molecule in a biological sample. In particular, the invention provides for methods of detecting tissue-typing antigens in donor tissue or recipient tissue using these multiple sets of microparticles.Type: ApplicationFiled: May 2, 2008Publication date: June 4, 2009Applicant: ONE LAMBDA, INC.Inventors: Jar-How Lee, Terrence Chen, Thoa Nong
-
Publication number: 20090011437Abstract: The invention is directed to methods of screening for HLA antibodies comprising detecting antibodies specific for native HLA antigens and denatured HLA antigens. The invention also provides for method of predicting whether a transplant recipient has an increased risk for rejecting the transplanted organ.Type: ApplicationFiled: June 27, 2008Publication date: January 8, 2009Applicant: ONE LAMBDAInventors: Jar-How Lee, Rui Pei, Thoa Nong
-
Patent number: 6514714Abstract: The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.Type: GrantFiled: April 17, 2000Date of Patent: February 4, 2003Assignee: One LambdaInventors: Jar-How Lee, Rui Pei
-
Publication number: 20010019825Abstract: The invention provides methods for detecting target nucleic acid sequences with diagnostic primers including priming regions and probe regions which are complementary to target and reference regions respectively on a sample nucleic acid strand wherein the probe region is located 5′ to the priming region which is complementary to a reference nucleic acid sequence which is 3′ to the target nucleic acid sequence on the sample nucleic acid strand wherein when said reference nucleic acid sequence is contiguous with said target nucleic acid sequence on the sample nucleic acid strand then the priming region and probe region on the diagnostic probe are separated by a spacer region of nucleic acid.Type: ApplicationFiled: March 26, 2001Publication date: September 6, 2001Applicant: One LambdaInventors: Jar-How Lee, Lindley Blair